Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. (Nasdaq: HIT) files a range of reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed, Nevada-incorporated InsurTech platform company. Its SEC filings provide detailed information on financial performance, governance, equity plans, and material corporate events related to its AI-enabled healthcare and insurance marketplace.
On this page, you can review Health In Tech’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss revenues, operating expenses, cash flows, and segment-related data for its insurance technology platform. These filings also describe risk factors, business strategy, and the company’s focus on process simplification and automation for insurers, brokers, and TPAs.
Health In Tech’s current reports on Form 8-K document specific events such as earnings announcements, investor presentations, stockholder meetings, equity incentive plan amendments, restricted stock awards tied to new initiatives and programs, and changes in executive roles. For example, 8-K filings describe the company’s annual meeting voting results, grants of restricted stock for new initiatives, and terminations or appointments of certain officers.
Investors interested in ownership and governance can use proxy materials such as the DEF 14A definitive proxy statement to understand board elections, equity plan proposals, auditor ratification, and voting structures for Class A and Class B common stock. These documents outline how Health In Tech manages compensation, board composition, and stockholder rights.
Stock Titan enhances access to these filings with AI-powered summaries that explain key points from lengthy documents, helping users quickly interpret complex sections of 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new filings for HIT appear promptly, while structured views of forms such as 8-K and proxy statements make it easier to track developments in Health In Tech’s InsurTech operations, capital structure, and governance over time.
Health In Tech, Inc. reported Q3 2025 results, showing strong growth and continued profitability. Revenue reached $8,490,093, up from $4,458,921 a year ago, while gross profit rose to $5,143,816 from $3,479,293. Operating expenses increased to $4,650,293 from $3,040,411 as the company invested in growth and platform capabilities. Net income was $452,176, compared with $376,086 in Q3 2024.
For the nine months, revenue was $25,818,926 versus $14,586,342, with net income of $1,581,399 versus $814,629, reflecting expanded SMR program fees and higher ICE underwriting revenue. Cash and cash equivalents were $8,023,613, supported by $2,682,602 provided by operating activities and offset by $2,358,213 invested in software development. The company recorded contra revenue tied to a carrier portfolio adjustment of $1,413,345 in Q3 and $2,369,088 year-to-date, with an $869,088 refund liability recorded. As of November 10, 2025, shares outstanding were 45,208,808 Class A and 11,700,000 Class B.
Health In Tech, Inc. furnished an earnings call transcript under Item 7.01. The call, held on November 10, 2025, covered financial and operating results for the quarter ended September 30, 2025. The transcript is included as Exhibit 99.1.
The information is deemed “furnished,” not “filed,” under the Exchange Act. A replay is available via the Company’s Investor Relations site through approximately February 8, 2026.
Health In Tech, Inc. (HIT) furnished an update on its quarterly results. The company reported that it issued a press release announcing results for the quarter ended September 30, 2025, and made that release available as Exhibit 99.1.
The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). The information in these items, including Exhibit 99.1, is expressly stated as “furnished” and not “filed” under the Exchange Act. The filing also includes customary forward‑looking statements language referring to risks described in the company’s periodic reports.
Health In Tech, Inc. (HIT) furnished an investor presentation under Regulation FD, making it available as Exhibit 99.1 to an 8-K. The materials are expressly deemed “furnished” and not “filed” under the Exchange Act, which means they are not subject to Section 18 liability and are not incorporated by reference into other filings. The company also included customary forward-looking statements language outlining risks referenced in prior SEC reports.
Health In Tech, Inc. (HIT) reported an insider equity award. On 11/05/2025, the company’s CISO, Michael Clarkson, received 8,000 restricted shares of Class A Common Stock coded “A” at a price of $0.00 under the Health in Tech Equity Incentive Plan. Following the grant, he beneficially owns 8,000 shares, held directly.
The restricted shares vest in equal monthly installments over twelve months, commencing on November 1, 2025, contingent on continued service through each vesting date. This filing reflects routine equity compensation for an officer rather than an open‑market transaction.
Health In Tech (HIT) disclosed an initial insider ownership filing on Form 3 for Michael Clarkson, the company’s CISO. The filing states that no securities are beneficially owned by the reporting person as of the event date 11/01/2025.
The Form 3 was filed by one reporting person in the capacity of an officer. No non-derivative or derivative holdings were reported.
Insider transactions by director William D. Howard at Health In Tech, Inc. (HIT)
The reporting person, a director, disposed of 28,159 restricted shares of Class A common stock that were subject to pro-rata forfeiture upon the annual stockholders meeting held on 10/03/2025. Five days later, on 10/08/2025, the director acquired 5,730 restricted shares at a price of $3.49 per share under the company’s Equity Incentive Plan. After these transactions the director beneficially owns 106,045 shares of Class A common stock.
Insider transactions by Director Timothy Hayes at Health In Tech, Inc. (HIT)
Director Timothy Hayes reported a disposition and a later acquisition of Class A common stock. On 10/03/2025 he disposed of 28,159 restricted shares that were forfeitable pro rata at the issuer's annual meeting, leaving 100,315 shares beneficially owned. On 10/08/2025 he acquired 5,730 restricted shares at a purchase price of $3.49 per share; those newly granted restricted shares vest quarterly from the grant date subject to continued service. The filing shows Hayes remains a significant insider and that his post-transaction holdings total 106,045 shares, combining previously owned and newly granted restricted stock.
Insider transactions by Director Sanjay K. Shrestha at Health In Tech, Inc. (HIT). The form reports a disposition of 65,469 Class A common shares on 10/03/2025 that were restricted shares subject to forfeiture tied to the annual stockholders meeting. The filing also shows an acquisition of 5,730 restricted Class A shares on 10/08/2025 at a purchase price of $3.49 per share; those restricted shares vest quarterly from the grant date with continued service. After these transactions the reporting person beneficially owned 68,735 Class A shares on a direct basis.
Health In Tech, Inc. reported results of its 2025 annual stockholder meeting. As of the August 6, 2025 record date, 56,389,291 shares were outstanding, split between 44,689,291 Class A shares with one vote each and 11,700,000 Class B shares with ten votes each.
Stockholders representing about 99.33% of voting power, or 161,619,722 votes, were present, establishing a strong quorum. All five director nominees were re-elected with roughly 148 million votes cast in favor for each and minimal abstentions, with broker non-votes of 1,873,265.
Stockholders approved an amendment to the 2024 Equity Incentive Plan, raising the Class A share reserve for awards from 7,677,849 to 10,677,849 and allowing issuance of up to 2,000,000 Class B shares and related options to executive officers. They also ratified MaloneBailey, LLP as independent auditors for the year ending December 31, 2025, with 161,551,973 votes for, 33,314 against, and 34,446 abstentions.